Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a bone drug help men with enlarged prostate?

NCT ID NCT06944145

First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 35 times

Summary

This study tests whether adding raloxifene (a drug used for bone health) to finasteride (a standard BPH drug) works better than finasteride alone for men with an enlarged prostate. About 242 adults will take either the combo or finasteride plus a placebo for 12 months. The main goal is to see if symptoms improve by at least 3 points on a standard symptom scale.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOWER URINARY TRACK SYMPTOMS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beth Israel Deaconess Medical Center

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

finasteride and raloxifene

What this could lead to

If successful, this combination could offer a new treatment option for men with BPH who don't respond to finasteride alone.

What could go wrong

This is a mid-stage trial with 242 participants, so results may not apply to everyone. Raloxifene also carries a risk of blood clots, which limits its use.

Conditions

The condition(s) this trial relates to.

benign prostatic hyperplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.